JP2023552791A5 - - Google Patents

Info

Publication number
JP2023552791A5
JP2023552791A5 JP2023534648A JP2023534648A JP2023552791A5 JP 2023552791 A5 JP2023552791 A5 JP 2023552791A5 JP 2023534648 A JP2023534648 A JP 2023534648A JP 2023534648 A JP2023534648 A JP 2023534648A JP 2023552791 A5 JP2023552791 A5 JP 2023552791A5
Authority
JP
Japan
Prior art keywords
alkyldiyl
peg
alkyl
immunocomplex
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023534648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552791A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062833 external-priority patent/WO2022125915A1/en
Publication of JP2023552791A publication Critical patent/JP2023552791A/ja
Publication of JP2023552791A5 publication Critical patent/JP2023552791A5/ja
Withdrawn legal-status Critical Current

Links

JP2023534648A 2020-12-11 2021-12-10 抗her2免疫複合体、及びその使用 Withdrawn JP2023552791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124421P 2020-12-11 2020-12-11
US63/124,421 2020-12-11
PCT/US2021/062833 WO2022125915A1 (en) 2020-12-11 2021-12-10 Anti-her2 immunoconjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2023552791A JP2023552791A (ja) 2023-12-19
JP2023552791A5 true JP2023552791A5 (https=) 2024-12-05

Family

ID=79425413

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534648A Withdrawn JP2023552791A (ja) 2020-12-11 2021-12-10 抗her2免疫複合体、及びその使用

Country Status (6)

Country Link
US (1) US20240042050A1 (https=)
EP (1) EP4259211A1 (https=)
JP (1) JP2023552791A (https=)
CN (1) CN116897054A (https=)
CA (1) CA3200320A1 (https=)
WO (1) WO2022125915A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023154318A1 (en) * 2022-02-09 2023-08-17 Bolt Biotherapeutics, Inc. Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof
WO2024173384A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
AU2019337654A1 (en) * 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
JP7558205B2 (ja) * 2019-06-13 2024-09-30 ボルト バイオセラピューティクス、インコーポレーテッド 高分子支持アミノベンズアピン化合物
US20200390899A1 (en) * 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
US20230293716A1 (en) * 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof

Similar Documents

Publication Publication Date Title
JP2023553421A5 (ja) 抗cea免疫複合体、及びその使用
JP2024523453A5 (https=)
JP2022553702A5 (https=)
JP2023552792A5 (https=)
JP2022537158A5 (https=)
JP2022549510A5 (https=)
JP2023524271A5 (https=)
JP2023105175A (ja) グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
CA3186295A1 (en) Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
JP2024059609A5 (https=)
IL312845B1 (en) Extacan derivatives, charge-linkers, and their conjugates
JP2022546110A5 (https=)
JP2024533356A5 (https=)
CA3044898A1 (en) Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
RU2748992C2 (ru) Системы доставки для контролируемого высвобождения лекарственного средства
JP2023552791A5 (https=)
JP2023527962A5 (https=)
JP2024511088A5 (https=)
JP2022554094A5 (https=)
JP2019502650A5 (ja) 抗ErbB2抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用
HRP20230275T1 (hr) Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina
JP2023552790A5 (https=)
JP2024501453A5 (https=)
CA2338000C (en) Water-soluble 4-thio-maleimido derivatives and methods for their production
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途